MEET THE TEAM

MANAGEMENT TEAM

Our team is made up of Chemists and Chemical Engineers with expertise in polymer science, organic, analytical and medicinal chemistry.  Our leaders are experienced in managing industries through various stages of growth.

DEFNE GARNER, CA
DEFNE GARNER, CA
Director, Finance
JEANNETTE HO
JEANNETTE HO
Vice President, Operations
WENDY NAIMARK, Ph.D.
WENDY NAIMARK, Ph.D.
Vice President, R&D
THOMAS P. REEVES
THOMAS P. REEVES
President & CEO
DR. PAUL SANTERRE, Ph.D.
DR. PAUL SANTERRE, Ph.D.
Chief Scientific Officer
FRANK SHANNON
FRANK SHANNON
Vice President, Clinical Research and Regulatory/Quality Affairs
MARK STEEDMAN
MARK STEEDMAN
Vice President, Business Development

DEFNE GARNER, CA

Director, Finance

Defne comes to Interface Biologics Inc. with both industry and audit experience. Most recently, she worked as Assistant Controller, Latin America, at SAS Institute (Canada) Inc., a subsidiary of one of the largest private technology companies worldwide, where she managed the coordination, consolidation, preparation and analysis of Latin American regional financial management reports for seven Latin American subsidiaries. Prior to SAS, she worked as a Senior Accountant, Consumer Markets, at KPMG LLP. She holds a B.Sc. Honours Biotechnology/Chartered Accountancy degree as well as a Masters of Accounting from the University of Waterloo and is a CPA, CA with the Institute of Chartered Accountants of Ontario.

JEANNETTE HO

Vice President, Operations

Jeannette is a charter member of the Interface Biologics scientific team. During her tenure, she has served as Director of Research and Development, Director of Operations and leads the Endexo™ development team. Jeannette was involved in developing Endexo™ technology during her graduate studies at the University of Toronto. She was also President of Jycho Surface Technologies, Inc., the company that began the scale-up and commercialization of the Endexo™ technology. She brings expertise in surface modifying macro-molecule (SMM) technology, biomaterials, polymer science, industrial processing and device manufacturing. Jeannette holds a B.A.Sc. in Chemical Engineering from the University of Waterloo and a M.A.Sc. from the University of Toronto.

WENDY NAIMARK, Ph.D.

Vice President, R&D

Wendy recently joined IBI, bringing a wealth of experience from having worked in both large and small medical device companies. She spent 11 years at Boston Scientific in increasingly senior management and R&D roles in the areas of Interventional Cardiology, Peripheral Interventions, Imaging, Endosurgery, Urology/Women’s health and Neuurovascular. Wendy most recently served for five years as Senior Director, Clinical and Preclinical Sciences at 480 Medical, an early stage drug delivery device company in the cardiovascular space. Wendy received her MSc and PhD from the University of Toronto in Biomaterials. She is the inventor of 27 US patents and author of 12 peer-reviewed publications.

THOMAS P. REEVES

President & CEO

Thomas P. Reeves joined Interface Biologics in November of 2008 as President and Chief Executive Officer. Tom brings a wealth of experience in running different companies in a variety of industries through various stages of growth. Most recently, he was President and COO of Occulogix, Inc. (NASDAQ: OCCX) a medical device company where he was instrumental in their Initial Public Offering raising over $100 million. Prior to OccuLogix, Mr. Reeves was the President of Borderfree, an international e-commerce service provider which was sold to Canada Post in 2004. Mr Reeves has also led Beamscope Canada Inc., Merisel Canada, Merisel Europe, and Merisel’s UK operation. Mr. Reeves started his career with the Boston Consulting Group (BCG) in San Francisco. He holds a BA in Economics, magna cum laude, from Harvard University and an MA in International Relations from the Australian National University.

Tom Reeves - EY Entrepreneur Of The Year 2014 Finalist

DR. PAUL SANTERRE, Ph.D.

Chief Scientific Officer

Dr. Santerre founded Interface Biologics Inc. in 2001 to develop improved medical implants based on his innovative research in polymer chemistry. Dr. Santerre is responsible for the strategic direction of research and development at Interface. Previously, Dr. Santerre was the manager of the materials development laboratory at the University of Ottawa and developed technology for the Ottawa Heart Institute artificial heart (World Heart Corporation). He is currently a full professor of biomaterials with appointments at the Faculty of Dentistry and the Institute for Biomaterials and Biomedical Engineering at the University of Toronto. He is an expert in the areas of physical, surface and biological characterization of polymers, polymer synthesis, material biocompatibility, drug polymers, and medical device manufacturing.

Dr. Paul Santerre, PhD wins the 2014 Ernest C. Manning $100,000 Principal Award

The Endexo Story from Angiodynamics

FRANK SHANNON

Vice President, Clinical Research and Regulatory/Quality Affairs

Frank Shannon re-joined Interface Biologics in May 2016, bringing more than 20 years of experience in clinical development, regulatory affairs and quality assurance in the pharmaceutical and medical device industries. He has led the design, execution, analysis, and reporting of numerous clinical trials and outcomes research studies with industry, government and NGO sponsors.

Frank has worked for large and medium pharmaceutical companies including Ciba-Geigy, Genentech, Roche and Boehringer Ingelheim where he led Medical Affairs for cardiovascular and cerebrovascular disease areas in Canada, including late phase clinical development projects, globally. Subsequently, he moved to the medical device sector, joining Occulogix as the Director of Clinical and Outcomes Research. More recently, he held executive positions in Regulatory Affairs and Quality Assurance at St. Jude Medical and Baxter Corporation, in Canada, prior to rejoining Interface Biologics in 2016. Following his bachelor’s degree in Psychology (Neurosciences) at Brock University, Frank undertook graduate studies in Epidemiology at the University of Toronto and the Institute for Clinical Evaluative Sciences.

MARK STEEDMAN

Vice President, Business Development

Mark coordinated the formation of the company in December 2001. He negotiated licensing terms with the University of Toronto, prepared the terms of the seed capital funding, and organized the company for operations beginning in January 2002. Mark is responsible for managing the financing and business aspects of the corporation. He raised $12M in seed capital for the corporation. He has taken the staff of Interface from 0 to 15 people and helped recruit the senior management team. Mr. Steedman was instrumental in landing early deals with several large medical device manufacturers, and oversaw company operations from early R&D to its first revenues in 2004. Mark holds degrees in Applied Science in Engineering, a Bachelor of Arts in Biology both from Queen’s University and an MBA from Wilfrid Laurier University.

CAREERS

Interface Biologics Inc. develops transformative polymer based technologies that improve the safety and effectiveness of medical devices. Our company environment is fast-paced, our culture is entrepreneurial, and our people are dedicated to the achievement of excellent scientific and commercial results.

We post all open positions on this website, and regularly review applications for employment from experienced individuals interested in working on challenging projects. We thank all who express an interest in joining the company. Due to the volume of applications, only those individuals chosen for an initial interview will be contacted

No matchs found.

We are always looking for talented chemists and chemical engineers to join our growing team.

Please submit resumes in confidence to
careers@interfacebiologics.com

Arthur L. Rosenthal, Chair
Arthur L. Rosenthal, PhD, joined IBI’s Board of Directors in July 2009 and has been Chairman since 2011. He is also Non-Executive Director and Chair of Compensation Committee for LivaNova, plc, a UK global medical technology company. Prior, Dr. Rosenthal served on the Cyberonics board of directors as a Non-Executive Director and Chair of the Compensation Committee from January 2007 to October, 2015. Since June 2010, he has served as Professor of Practice in the Biomedical Engineering Department at Boston University. Since December 2011, he has also served as CEO of gEyeCue, Ltd., which he co-founded, a development stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer screening. From 2009 to 2012, Arthur was President and CEO and then executive vice chairman of Cappella Medical Devices Ltd. (now ArraVasc Ltd.), a development-stage company focused on novel device solutions for coronary artery disease. From 2002-2008, Arthur was CEO of Labcoat, Ltd. until its acquisition by Boston Scientific Corporation in December 2008. From 1994-2005, Arthur was with Boston Scientific, retiring Senior Vice President, Chief Scientific Officer, and Executive Committee Member.

Sandra Beach Lin, Retired President & CEO, Calisolar Inc.
Ms. Beach Lin brings 30+ years of polymer, technology and innovation experience to the IBI Board, having served in C-suite positions at Celanese Corporation and AveryDennison, and in senior executive roles at Honeywell International and Alcoa. She also brings private company experience to IBI as the retired President & CEO of Calisolar Inc. (now Silicor Materials), a privately-held provider of solar silicon. Ms. Beach Lin is a member of the Board of Directors of WESCO International (NYSE: WCC), American Electric Power (NYSE: AEP) and PolyOne Corporation (NYSE:POL).

Dion Madsen, Senior Managing Partner, Healthcare Fund, BDC Capital
Dion Madsen is Senior Managing Partner of the Healthcare Fund at BDC Capital. Dion brings over 25 years of senior management experience as a financial executive and venture investor, formerly as Founder and Managing Director of Physic Ventures, and as Managing Director of Unilever Technology Ventures, Unilever’s North American corporate venture fund. Prior to Unilever, Dion was Director of Investor Relations at Chiron Corporation where he also worked in Corporate Development, building a new strategy for the company’s $500M BioPharma business. Before moving to San Francisco, Dion spent five years as Partner of RBC Capital Partners’ Life Sciences Venture Fund, the first third-party capital fund in RBC Capital Partners’ history.

Dion is a founding member of C100, a select group of the top 100 Canadians in the San Francisco Bay area, and has sat on the boards of directors of many venture capital funds and companies in the pharmaceutical and health care industries. He has also held the roles of M&A Advisor, Strategic Consultant and CFO for a biotechnology company. He currently sits on the Board of Directors of Interface Biologics, Agrisoma Biosciences, Phemi Health Systems, Xagenic Inc., Zymeworks and Chromatin. He is also a selection committee member of the San Francisco Canadian Technology Accelerator.

Dion is a CFA® charterholder and has a Bachelor of Commerce in Finance and Marketing from the University of Saskatchewan.
Leonard Pinchuk, Ph.D., D.Sc., (h.c.), NAE
Dr.  Leonard Pinchuk is a serial inventor and entrepreneur with 115 U.S. patents and 10 companies that he co-founded.  His major accomplishments include the invention of the modern-day angioplasty balloon, the helical wire stent, the modular stent-graft, a drug-eluting stent (TAXUS), several biomaterials and a novel glaucoma shunt. He received a B.Sc. in chemistry from McGill University (1976), a Ph.D. interdisciplinary in Engineering and Chemistry from the University of Miami (1984) and an honorary Doctor of Science degree from McGill University (2005).  He was inducted into the National Academy of Engineering in 2012.   Dr. Pinchuk began his career in 1983 at Cordis Corporation and left in 1987 to co-found Corvita Corporation (angioplasty catheters, stents, stent-grafts), which went public in 1994, was acquired by Pfizer, Inc. (1996) and then sold to Boston Scientific (1998).  Dr. Pinchuk founded Innovia LLC (2002), which incubated and spun off eight new companies (intraocular lenses, glaucoma shunts, other catheters and biomaterials).  He currently spends most of his time working in the field of glaucoma in one of his spin-off companies, InnFocus, Inc.

Thomas P. Reeves, President & CEO
Mr. Reeves is President and CEO of Interface Biologics. A more detailed description of his credentials is included in the "Our Management" section of this website.

Paul Santerre, Ph.D., Chief Scientific Officer, Interface Biologics Inc.
Dr. Santerre is the founder and Chief Scientific Officer of Interface Biologics and a full professor of biomaterials at the University of Toronto. A more detailed biography is included in the “Our Management” section of this website.


Phil Reddon, Managing Partner, Covington Capital Corporation
Phil joined Covington in 2002 as Vice President, Investments. Before joining Covington, Phil was Managing Director at Bank of Montreal Capital Corporation for six years leading the firm’s technology investment team. Prior to that, Phil was with a Canadian crown corporation where he was involved in lending and investing in technology companies for 6 years. Phil has over 20 years of direct investment experience in early stage technology companies and has sat on the board and driven numerous investments from initial funding, through follow on rounds of financing and exits. Phil has an B.A. from the University of Western Ontario and an H.B.A. from the University of Windsor.

Pieter Wolters, Managing Director, DSM Venturing, VP DSM Innovation Center
Pieter joined DSM in 2012 as Managing Director DSM Venturing and VP at the DSM Innovation Center. Before DSM he gained fifteen years of “startup through commercialization” experience as CEO at OrthAlign, Inc., Aliso Viejo, CA, a pioneer in orthopedic surgical navigation and at IsoTis, Inc., Irvine, CA, a leading regenerative medicine company.   Pieter worked the first ten years of his career in international M&A and investment management and holds a law degree from Leiden University, NL. He works and lives in (greater) Boston, MA, USA.

J. Paul Santerre, Ph.D. (Biomaterials)
Professor of Biomaterials and Director of the Institute for Biomaterials and Biomedical Engineering at the University of Toronto. Founder of Interface Biologics Inc., in 2001.

John Denstedt, M.D. (Urology)
Urologist and Chairman of the Department of Surgery at The University of Western Ontario; author of over 200 scientific articles and book chapters.

Tony Khoury, M.D. (Urology)
Chief of Pediatric Urology at CHOC and UC Irvine Medical Center; Former Chief of Paediatric Urology at The Hospital for Sick Children; Professor of Surgery at the University of Toronto.

Rosalind Labow, Ph.D. (Biochemistry)
Director, Taichman Laboratory, University of Ottawa Heart Institute; Professor, Department of Surgery and Departments of Biochemistry, Microbiology and Immunology, University of Ottawa.

Robert M.A. Richardson, M.D. (Nephrology)
Professor of Medicine, University of Toronto; Director of Hemodialysis for The University Health Network (3 Toronto teaching hospitals) since 1990.
Marc W. Mittelman, Ph.D. (Microbiology)
Professor of Microbiology at Bristol College, Boston, MA; Visiting Professor at Laboratory of Applied Microbiology at Harvard University.

Leonard Pinchuk, Ph.D. (Biomaterials)
Co-founder and President/CEO of Innovia and its affiliates; world-renowned expert in the field of biomaterials and medical devices with over 80 patents in this area.

Robert Schwartz, M.D. (Interventional Cardiology)
Medical Director, Minneapolis Heart Institute Foundation, Professor of Medicine, University of Minnesota and Cardiologist, Minneapolis Heart Institute.

Bradley Strauss, M.D. (Interventional Cardiology)
Chairman, Cardiovascular Research Sunnybrook Health Sciences Centre; Reichmann Research Chair in Cardiovascular Sciences at the University of Toronto.

Kieran J. Murphy, M.D. (Interventional Radiology)
Vice Chair and Chief of Medical Imaging at the University of Toronto; author of over 100 papers, 12 computer programs, and several book chapters.
Powered by Innovasium